June 15, 2005Circulation
Trial to Evaluate the Management of Paroxysmal Supraventricular Tachycardia During an Electrophysiology Study With Tecadenoson
Why the study?
Does tecadenoson bolus improve the therapeutic conversion rate to normal sinus rhythm in patients with inducible PSVT during an electrophysiology study?
Population
181 patients with a history of symptomatic paroxysmal supraventricular tachycardia and inducible PSVT at the…
Comparison
Tecadenoson bolus. The second bolus was… vs Placebo
Design
RCT, randomized, double-blind, placebo-controlled
Authors
Discussion
Loading...
Member takes
Implication
Tecadenoson boluses rapidly convert inducible PSVT; confirms selective A1-adenosine agonism as effective in the electrophysiology laboratory.
Structured PICO
Does tecadenoson bolus improve the therapeutic conversion rate to normal sinus rhythm in patients with inducible PSVT during an electrophysiology study?
P
Population
181 patients with a history of symptomatic paroxysmal supraventricular tachycardia (PSVT) and inducible PSVT at the time of a clinically indicated electrophysiology study.
I
Intervention
Tecadenoson bolus (five 2-dose regimens: 75/150, 150/300, 300/600, 450/900, 900/900 microg). The second bolus was administered only if PSVT persisted for 1 minute after the first bolus.
C
Comparator
Placebo
O
Outcome
Therapeutic conversion rate of PSVT to normal sinus rhythm
Tecadenoson is a safe and effective A1-adenosine receptor agonist for the rapid termination of induced PSVT during electrophysiology studies.
Cite This Study
Ellenbogen et al. (2005) studied this question.